- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging MRI-Based Technology for Assessing Muscle and Fat Gets FDA 510(k) Clearance
Utilizing biomarkers from magnetic resonance imaging (MRI) exams, AMRA Medical’s BCP Scan reportedly provides precise measurements of muscle and fat.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the BCP (Body Composition Profile) Scan, a technology that enables clinicians to obtain accurate muscle and fat measurements from magnetic resonance imaging (MRI), according to AMRA Medical.
In contrast to obtaining a body mass index (BMI) or waist circumference number, AMRA Medical said its BCP Scan offers specific measurements of muscle, fat, and liver fat volumes. The company noted these measurements may help clinicians educate patients on associated health risks and initiate conversations about lifestyle changes to mitigate these risks.
For example, the BCP Scan can reportedly identify people with high visceral fat and low liver fat, a combination associated with a high heart disease risk, according to AMRA Medical. The company also suggested that the BCP Scan can help monitor weight loss efforts for obese people by determining whether they are losing visceral fat or if they are only losing subcutaneous fat.
AMRA Medical says its protocol for the BCP Scan only adds a couple of minutes to a prescribed MRI exam and generates a report that compares the patient’s body composition measurements to normative values from the company’s reference database as well as others of the same sex and body habitus.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
